XLO NASDAQ
Xilio Therapeutics, Inc.
1W: +5.8%
1M: -3.2%
3M: +1333.1%
YTD: +1117.8%
1Y: +851.8%
3Y: +158.0%
$8.44
+0.26 (+3.18%)
After Hours: $8.54 (+0.10, +1.18%)
Weekly Expected Move ±9.3%
$7
$8
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$50.5M
52W Range6.468-16.1
Volume24,045
Avg Volume48,848
Beta-0.13
Dividend—
Analyst Ratings
Company Info
CEORene Russo
Employees64
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-22
Websitexiliotx.com
828 Winter Street
Waltham, MA 02451
US
Waltham, MA 02451
US
617 430 4680
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Latest News
Cancer Stocks That Are Advancing the Future of Oncology Care
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Blanchard Cheryl R | A-Award | 10,000 | $8.40 | 2026-04-15 |
| Blanchard Cheryl R | 0 | — | 2026-04-15 | |
| Shannon James Samuel | P-Purchase | 5,000 | $8.79 | 2026-03-26 |
| Brennan Kevin M. | S-Sale | 1,826 | $0.64 | 2026-01-02 |
| Frankenfield Christo | S-Sale | 7,030 | $0.64 | 2026-01-02 |